 | Up a level |
Tsakiris, Dimitrios A; Gavriilaki, Eleni; Chanou, Ioanna; Meyer, Sara C (2024). Hemostasis and complement in allogeneic hematopoietic stem cell transplantation: clinical significance of two interactive systems. (In Press). Bone marrow transplantation Nature Publishing Group 10.1038/s41409-024-02362-8
Dunbar, Andrew J; Bowman, Robert L; Park, Young C; O'Connor, Kavi; Izzo, Franco; Myers, Robert M; Karzai, Abdul; Zaroogian, Zach; Kim, Won Jun; Fernandez-Maestre, Ines; Waarts, Michael R; Nazir, Abbas; Xiao, Wenbin; Codilupi, Tamara; Brodsky, Max; Farina, Mirko; Cai, Louise; Cai, Sheng F; Wang, Benjamin; An, Wenbin; ... (2024). Jak2V617F Reversible Activation Shows Its Essential Requirement in Myeloproliferative Neoplasms. Cancer discovery, 14(5), pp. 737-751. American Association for Cancer Research 10.1158/2159-8290.CD-22-0952
Codilupi, Tamara; Szybinski, Jakub; Arunasalam, Stefanie; Jungius, Sarah; Dunbar, Andrew C; Stivala, Simona; Brkic, Sime; Albrecht, Camille; Vokalova, Lenka; Yang, Julie L; Buczak, Katarzyna; Ghosh, Nilabh; Passweg, Jakob R; Rovo, Alicia; Angelillo-Scherrer, Anne; Pankov, Dmitry; Dirnhofer, Stephan; Levine, Ross L; Koche, Richard and Meyer, Sara C (2024). Development of resistance to type II JAK2 inhibitors in MPN depends on AXL kinase and is targetable. Clinical cancer research, 30(3), pp. 586-599. American Association for Cancer Research 10.1158/1078-0432.CCR-23-0163
Konantz, Martina; Williams, Margaret; Merkel, Tamara; Reiss, Antonia; Dirnhofer, Stefan; Meyer, Sara C; Valent, Peter; George, Tracy I; Tzankov, Alexandar; Hartmann, Karin (2023). Increased TIM-3 and GAL-9 serum levels in patients with advanced systemic mastocytosis. Journal of allergy and clinical immunology, 152(4), pp. 1019-1024. Elsevier 10.1016/j.jaci.2023.07.001
Jungius, Sarah; Adam, Franziska C; Grosheintz, Kerstin; Medinger, Michael; Buser, Andreas; Passweg, Jakob R; Halter, Jörg P; Meyer, Sara C (2023). Characterization of engraftment dynamics in myelofibrosis after allogeneic hematopoietic cell transplantation including novel conditioning schemes. Frontiers in oncology, 13(1205387), p. 1205387. Frontiers Research Foundation 10.3389/fonc.2023.1205387
Konantz, Martina; Merkel, Tamara; Meyer, Sara C; Hartmann, Karin (2023). MRGPRX2: A novel biomarker in mastocytosis? The journal of allergy and clinical immunology. In practice, 11(2), pp. 669-671. Elsevier 10.1016/j.jaip.2022.10.053
Kirsch, Mark; Stehle, Gregor T; Konantz, Martina; Passweg, Jakob; Dirnhofer, Stefan; Meyer, Sara C; Hartmann, Karin (2022). Presence of neoplastic mast cells in ascites in advanced systemic mastocytosis. The journal of allergy and clinical immunology. In practice, 10(11), 3035-3038.e1. Elsevier 10.1016/j.jaip.2022.07.014
Parmigiani, Elena; Ivanek, Robert; Rolando, Chiara; Hafen, Katrin; Turchinovich, Gleb; Lehmann, Frank Michael; Gerber, Alexandra; Brkic, Sime; Frank, Stephan; Meyer, Sara C; Wakimoto, Hiroaki; Günel, Murat; Louvi, Angeliki; Mariani, Luigi; Finke, Daniela; Holländer, Georg; Hutter, Gregor; Tussiwand, Roxane; Taylor, Verdon and Giachino, Claudio (2022). Interferon-γ resistance and immune evasion in glioma develop via Notch-regulated co-evolution of malignant and immune cells. Developmental cell, 57(15), 1847-1865.e9. Elsevier 10.1016/j.devcel.2022.06.006
Adam, Franziska C; Szybinski, Jakub; Halter, Jörg P; Cantoni, Nathan; Wenzel, Friedel; Leonards, Katharina; Brkic, Sime; Passweg, Jakob R; Touw, Ivo; Maxson, Julia E; Meyer, Sara C (2022). Co-Occurring CSF3R W791* Germline and Somatic T618I Driver Mutations Induce Early CNL and Clonal Progression to Mixed Phenotype Acute Leukemia. Current oncology, 29(2), pp. 805-815. MDPI 10.3390/curroncol29020068
Bader, Michael Stephan; Meyer, Sara Christina (2022). JAK2 in Myeloproliferative Neoplasms: Still a Protagonist. Pharmaceuticals, 15(2) MDPI 10.3390/ph15020160
Person, Fermin; Meyer, Sara C.; Hopfer, Helmut; Menter, Thomas (2021). Renal post-mortem findings in myeloproliferative and myelodysplastic/myeloproliferative neoplasms. Virchows Archiv, 479(5), pp. 1013-1020. Springer 10.1007/s00428-021-03129-y
Stivala, Simona; Meyer, Sara C. (2021). Recent Advances in Molecular Diagnostics and Targeted Therapy of Myeloproliferative Neoplasms. Cancers, 13(20) MDPI AG 10.3390/cancers13205035
Brkic, Sime; Stivala, Simona; Santopolo, Alice; Szybinski, Jakub; Jungius, Sarah; Passweg, Jakob R; Tsakiris, Dimitrios; Dirnhofer, Stefan; Hutter, Gregor; Leonards, Katharina; Lischer, Heidi E L; Dettmer, Matthias S; Neel, Benjamin G; Levine, Ross L; Meyer, Sara C (2021). Dual targeting of JAK2 and ERK interferes with the myeloproliferative neoplasm clone and enhances therapeutic efficacy. Leukemia, 35(10), pp. 2875-2884. Springer Nature 10.1038/s41375-021-01391-2
Zeeh, Franziska C; Meyer, Sara C (2021). Current Concepts of Pathogenesis and Treatment of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms. Hämostaseologie, 41(3), pp. 197-205. Thieme 10.1055/a-1447-6667
Szybinski, Jakub; Meyer, Sara C. (2021). Genetics of Myeloproliferative Neoplasms. Hematology/oncology clinics of North America, 35(2), pp. 217-236. Elsevier 10.1016/j.hoc.2020.12.002
Brkic, Sime; Meyer, Sara C. (2021). Challenges and Perspectives for Therapeutic Targeting of Myeloproliferative Neoplasms. HemaSphere, 5(1), e516. Wolters Kluwer Health 10.1097/HS9.0000000000000516
Nienhold, Ronny; Ashcroft, Peter; Zmajkovic, Jakub; Rai, Shivam; Rao, Tata Nageswara; Drexler, Beatrice; Meyer, Sara C.; Lundberg, Pontus; Passweg, Jakob R; Leković, Danijela; Čokić, Vladan; Bonhoeffer, Sebastian; Skoda, Radek C (2020). MPN patients with low mutant JAK2 allele burden show late expansion restricted to erythroid and megakaryocytic lineages. Blood, 136(22), pp. 2591-2595. American Society of Hematology 10.1182/blood.2019002943
Stivala, Simona; Codilupi, Tamara; Brkic, Sime; Baerenwaldt, Anne; Ghosh, Nilabh; Hao-Shen, Hui; Dirnhofer, Stephan; Dettmer, Matthias S.; Simillion, Cedric; Kaufmann, Beat A; Chiu, Sophia; Keller, Matthew; Kleppe, Maria; Hilpert, Morgane; Buser, Andreas S; Passweg, Jakob R; Radimerski, Thomas; Skoda, Radek C; Levine, Ross L and Meyer, Sara C (2019). Targeting compensatory MEK/ERK activation increases JAK inhibitor efficacy in myeloproliferative neoplasms. The journal of clinical investigation, 129(4), pp. 1596-1611. American Society for Clinical Investigation 10.1172/JCI98785
Meyer, Sara C.; Drexler, Beatrice; Skoda, Radek C. (2019). [Myeloproliferative neoplasms - Update on diagnosis and treatment]. Therapeutische Umschau. Revue therapeutique, 76(9), pp. 487-495. Hogrefe 10.1024/0040-5930/a001128
Kunimoto, Hiroyoshi; Meydan, Cem; Nazir, Abbas; Whitfield, Justin; Shank, Kaitlyn; Rapaport, Franck; Maher, Rebecca; Pronier, Elodie; Meyer, Sara C.; Garrett-Bakelman, Francine E; Tallman, Martin; Melnick, Ari; Levine, Ross L; Shih, Alan H (2018). Cooperative Epigenetic Remodeling by TET2 Loss and NRAS Mutation Drives Myeloid Transformation and MEK Inhibitor Sensitivity. Cancer cell, 33(1), 44-59.e8. Cell Press 10.1016/j.ccell.2017.11.012
Nitulescu, Ioana I; Meyer, Sara C.; Wen, Qiang Jeremy; Crispino, John D; Lemieux, Madeleine E; Levine, Ross L; Pelish, Henry E; Shair, Matthew D (2017). Mediator Kinase Phosphorylation of STAT1 S727 Promotes Growth of Neoplasms With JAK-STAT Activation. EBioMedicine, 26, pp. 112-125. Elsevier 10.1016/j.ebiom.2017.11.013
Stivala, Simona; Gobbato, Sara; Infanti, Laura; Reiner, Martin F; Bonetti, Nicole; Meyer, Sara C.; Camici, Giovanni G; Lüscher, Thomas F; Buser, Andreas; Beer, Juerg H (2017). In response to the comment by Hechler et al.: Amotosalen/UVA pathogen inactivation technology reduces platelet activatability, induces apoptosis and accelerates clearance. Haematologica - the hematology journal, 102(12), e504-e505. Ferrata-Storti Foundation 10.3324/haematol.2017.181818
Stivala, Simona; Gobbato, Sara; Infanti, Laura; Reiner, Martin F; Bonetti, Nicole; Meyer, Sara C.; Camici, Giovanni G; Lüscher, Thomas F; Buser, Andreas; Beer, Jürg H (2017). Amotosalen/ultraviolet A pathogen inactivation technology reduces platelet activatability, induces apoptosis and accelerates clearance. Haematologica - the hematology journal, 102(10), pp. 1650-1660. Ferrata-Storti Foundation 10.3324/haematol.2017.164137
Meyer, Sara C. (2017). Mechanisms of Resistance to JAK2 Inhibitors in Myeloproliferative Neoplasms. Hematology/oncology clinics of North America, 31(4), pp. 627-642. Elsevier 10.1016/j.hoc.2017.04.003
Meyer, Sara C.; Steinmann, Eva; Lehmann, Thomas; Muesser, Patricia; Passweg, Jakob R; Skoda, Radek C; Tsakiris, Dimitrios A (2017). Anti-Platelet Factor 4/Heparin Antibody Formation Occurs Endogenously and at Unexpected High Frequency in Polycythemia Vera. BioMed research international, 2017, p. 9876819. Hindawi 10.1155/2017/9876819
Grisouard, Jean; Li, Sai; Kubovcakova, Lucia; Rao, Tata Nageswara; Meyer, Sara C; Lundberg, Pontus; Hao-Shen, Hui; Romanet, Vincent; Murakami, Masato; Radimerski, Thomas; Dirnhofer, Stephan; Skoda, Radek C (2016). JAK2 exon 12 mutant mice display isolated erythrocytosis and changes in iron metabolism favoring increased erythropoiesis. Blood, 128(6), pp. 839-851. American Society of Hematology 10.1182/blood-2015-12-689216
Shimizu, Takafumi; Kubovcakova, Lucia; Nienhold, Ronny; Zmajkovic, Jakub; Meyer, Sara C.; Hao-Shen, Hui; Geier, Florian; Dirnhofer, Stephan; Guglielmelli, Paola; Vannucchi, Alessandro M; Feenstra, Jelena D Milosevic; Kralovics, Robert; Orkin, Stuart H; Skoda, Radek C (2016). Loss of Ezh2 synergizes with JAK2-V617F in initiating myeloproliferative neoplasms and promoting myelofibrosis. The Journal of experimental medicine, 213(8), pp. 1479-1496. Rockefeller Univ. Press 10.1084/jem.20151136
Meyer, Sara C; Keller, Matthew D; Chiu, Sophia; Koppikar, Priya; Guryanova, Olga A; Rapaport, Franck; Xu, Ke; Manova, Katia; Pankov, Dmitry; O'Reilly, Richard J; Kleppe, Maria; McKenney, Anna Sophia; Shih, Alan H; Shank, Kaitlyn; Ahn, Jihae; Papalexi, Eftymia; Spitzer, Barbara; Socci, Nick; Viale, Agnes; Mandon, Emeline; ... (2015). CHZ868, a Type II JAK2 Inhibitor, Reverses Type I JAK Inhibitor Persistence and Demonstrates Efficacy in Myeloproliferative Neoplasms. Cancer cell, 28(1), pp. 15-28. Cell Press 10.1016/j.ccell.2015.06.006
Meyer, Sara C; Keller, Matthew D; Woods, Brittany A; LaFave, Lindsay M; Bastian, Lennart; Kleppe, Maria; Bhagwat, Neha; Marubayashi, Sachie; Levine, Ross L (2014). Genetic studies reveal an unexpected negative regulatory role for Jak2 in thrombopoiesis. Blood, 124(14), pp. 2280-2284. American Society of Hematology 10.1182/blood-2014-03-560441
Meyer, Sara C; Levine, Ross L (2014). Translational implications of somatic genomics in acute myeloid leukaemia. The lancet oncology, 15(9), e382-e394. Elsevier 10.1016/S1470-2045(14)70008-7
Meyer, Sara C.; Medinger, Michael; Halter, Jörg P; Baldomero, Helen; Hirsch, Hans H; Tzankov, Alexandar; Dirnhofer, Stephan; Passweg, Jakob R; Tichelli, André (2014). Heterogeneity in clinical course of EBV-associated lymphoproliferative disorder after allogeneic stem cell transplantation. Hematology, 19(5), pp. 280-285. Taylor & Francis 10.1179/1607845413Y.0000000123
Meyer, Sara C; Levine, Ross L (2014). Molecular pathways: molecular basis for sensitivity and resistance to JAK kinase inhibitors. Clinical cancer research, 20(8), pp. 2051-2059. American Association for Cancer Research 10.1158/1078-0432.CCR-13-0279
Waibel, Michaela; Solomon, Vanessa S; Knight, Deborah A; Ralli, Rachael A; Kim, Sang-Kyu; Banks, Kellie-Marie; Vidacs, Eva; Virely, Clemence; Sia, Keith C S; Bracken, Lauryn S; Collins-Underwood, Racquel; Drenberg, Christina; Ramsey, Laura B; Meyer, Sara C.; Takiguchi, Megumi; Dickins, Ross A; Levine, Ross; Ghysdael, Jacques; Dawson, Mark A; Lock, Richard B; ... (2013). Combined targeting of JAK2 and Bcl-2/Bcl-xL to cure mutant JAK2-driven malignancies and overcome acquired resistance to JAK2 inhibitors. Cell reports, 5(4), pp. 1047-1059. Cell Press 10.1016/j.celrep.2013.10.038
Meyer, Sara C.; O'Meara, Alix; Buser, Andreas S; Tichelli, André; Passweg, Jakob R; Stern, Martin (2013). Prognostic impact of posttransplantation iron overload after allogeneic stem cell transplantation. Biology of blood and marrow transplantation, 19(3), pp. 440-444. Elsevier 10.1016/j.bbmt.2012.10.012
Meyer, Sara C; Rovó, Alicia; Tsakiris, Dimitrios A; Scherer, Kathrin; Tichelli, André; Holbro, Andreas (2013). Severe cutaneous toxicity related to Eltrombopag. British journal of haematology, 160(3), pp. 412-414. Wiley 10.1111/bjh.12126
Scherer, Simone Rebekka; Faber, Katrin; Meyer, Sara Christina; Ceschi, Alessandro; Eckstein, Jens (2012). Severe Bradycardia: Patient Outfoxed by Lady's Glove. The American journal of medicine, 125(11), e3-e4. Elsevier 10.1016/j.amjmed.2012.02.026
Meyer, C. (2012). [Platelet inhibition in clinical practice]. Therapeutische Umschau. Revue therapeutique, 69(11), pp. 631-633. Hogrefe 10.1024/0040-5930/a000340
Forestier, Marc; Al-Tamimi, Mohammad; Gardiner, Elizabeth E; Hermann, Corinna; Meyer, Sara C.; Beer, Juerg H (2012). Diesel exhaust particles impair platelet response to collagen and are associated with GPIbα shedding. Toxicology in vitro, 26(6), pp. 930-938. Elsevier 10.1016/j.tiv.2012.04.009
Meyer, Sara Christina; Steveling, Esther Helen; D'Souza, Marcus; Hug, Balthasar L. (2012). Schmerzhafte Parese und Hautausschlag. Swiss medical forum, 12(36), pp. 694-695. EMH Schweizerischer Ärzteverlag AG 10.4414/smf.2012.01228
Meyer, Sara Christina; Stern, Martin (2011). [Proteins support stem cells - use of protein therapeutics in hematopoietic stem cell transplantation]. Therapeutische Umschau. Revue therapeutique, 68(11), pp. 641-649. Hogrefe 10.1024/0040-5930/a000224
Meyer, Sara C; Jeddi, Ramzi; Meddeb, Balkis; Gouider, Emna; Lämmle, Bernhard; Kremer Hovinga, Johanna A (2008). A first case of congenital TTP on the African continent due to a new homozygous mutation in the catalytic domain of ADAMTS13. Annals of hematology, 87(8), pp. 663-6. Berlin: Springer 10.1007/s00277-008-0496-6
Kremer Hovinga, Johanna A; Meyer, Sara C (2008). Current management of thrombotic thrombocytopenic purpura. Current opinion in hematology, 15(5), pp. 445-50. Hagerstown, Md.: Wolters Kluwer Lippincott Williams & Wilkins 10.1097/MOH.0b013e328309ec62
Meyer, S C; Sulzer, I; Lämmle, B; Kremer Hovinga, J A (2007). Hyperbilirubinemia interferes with ADAMTS-13 activity measurement by FRETS-VWF73 assay: diagnostic relevance in patients suffering from acute thrombotic microangiopathies. Journal of thrombosis and haemostasis, 5(4), pp. 866-7. Oxford: Blackwell 10.1111/j.1538-7836.2007.02438.x
